Intercept Pharmaceuticals (NASDAQ:ICPT) Earning Somewhat Positive Media Coverage, Study Finds

News coverage about Intercept Pharmaceuticals (NASDAQ:ICPT) has trended somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intercept Pharmaceuticals earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.5670427883612 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the headlines that may have effected Accern Sentiment’s analysis:

A number of brokerages recently commented on ICPT. Seaport Global Securities restated a “buy” rating and set a $136.00 price target on shares of Intercept Pharmaceuticals in a research note on Friday, October 6th. JMP Securities reiterated an “outperform” rating and issued a $140.00 target price (down from $150.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, September 26th. Jefferies Group reiterated a “buy” rating and issued a $275.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 20th. BidaskClub cut shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Finally, Citigroup set a $74.00 target price on shares of Intercept Pharmaceuticals and gave the stock a “hold” rating in a research note on Thursday, December 21st. Five research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the company. Intercept Pharmaceuticals has an average rating of “Hold” and an average target price of $140.24.

Intercept Pharmaceuticals (NASDAQ ICPT) traded up $0.64 during mid-day trading on Friday, hitting $54.95. 516,710 shares of the company traded hands, compared to its average volume of 707,831. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. Intercept Pharmaceuticals has a 52 week low of $52.11 and a 52 week high of $135.59. The company has a market cap of $1,380.00, a price-to-earnings ratio of -3.71 and a beta of -2.05.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The company had revenue of $41.33 million for the quarter, compared to analyst estimates of $36.95 million. During the same quarter last year, the firm earned ($3.59) EPS. The firm’s quarterly revenue was up 697.9% compared to the same quarter last year. equities analysts predict that Intercept Pharmaceuticals will post -13.36 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply